Open AccessPerspective, perceptions, and promulgation of biosimilars: A questionnaire-based study to assess and understand the current challenges of biosimilars to the potential and intended users
Author(s) -
K. K. Bhardwaj,
K Bangarurajan,
Tanveer Naved,
Satyendra Kumar Rajput
Publication year - 2020
Publication title -
journal of pharmacy and bioallied sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.268
H-Index - 36
eISSN - 0976-4879
pISSN - 0975-7406
DOI - 10.4103/jpbs.jpbs_11_20
Subject(s) - biosimilar , government (linguistics) , agency (philosophy) , globe , marketing , product (mathematics) , medicine , revenue , public relations , business , accounting , political science , social science , philosophy , linguistics , geometry , mathematics , sociology , ophthalmology
Biosimiliar, a copy of reference biological product, is making a buzz across the globe for its upper edge therapeutic usage. According to the market research report published by P&S Intelligence, biosimilars market is expected to generate $26.7 billion revenue by 2024, advancing at a CAGR of 29.6% during the forecast period. The first biosimilar to medicine Omnitrope, was approved in Europe by EMA (European Medicines Agency) in year 2006. Till date countries like US, China, Japan, India and many more have generated regulatory guidelines for biosimilars.